127 related articles for article (PubMed ID: 33258517)
1. Impact of mind-body treatment interventions on quality of life in neurofibromatosis patients: A systematic review and meta-analysis.
Wei G; Farooq J; Kumar A
Dermatol Ther; 2021 Jan; 34(1):e14613. PubMed ID: 33258517
[TBL] [Abstract][Full Text] [Related]
2. The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study.
Vranceanu AM; Merker VL; Plotkin SR; Park ER
J Neurooncol; 2014 Oct; 120(1):103-9. PubMed ID: 25022450
[TBL] [Abstract][Full Text] [Related]
3. Improvement in resiliency factors among adolescents with neurofibromatosis who participate in a virtual mind-body group program.
Lester EG; Macklin EA; Plotkin S; Vranceanu AM
J Neurooncol; 2020 Apr; 147(2):451-457. PubMed ID: 32078086
[TBL] [Abstract][Full Text] [Related]
4. Mind-body therapy via videoconferencing in patients with neurofibromatosis: An RCT.
Vranceanu AM; Riklin E; Merker VL; Macklin EA; Park ER; Plotkin SR
Neurology; 2016 Aug; 87(8):806-14. PubMed ID: 27449066
[TBL] [Abstract][Full Text] [Related]
5. Mind-Body Therapy via Videoconferencing in Patients With Neurofibromatosis: Analyses of 1-Year Follow-up.
Lester EG; Gates MV; Vranceanu AM
Ann Behav Med; 2021 Feb; 55(1):77-81. PubMed ID: 32421171
[TBL] [Abstract][Full Text] [Related]
6. Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.
Vranceanu AM; Manglani HR; Choukas NR; Kanaya MR; Lester E; Zale EL; Plotkin SR; Jordan J; Macklin E; Bakhshaie J
JAMA Netw Open; 2023 Jun; 6(6):e2320599. PubMed ID: 37378983
[TBL] [Abstract][Full Text] [Related]
7. Psychological resiliency explains the relationship between emotional distress and quality of life in neurofibromatosis.
Mace RA; Doorley J; Bakhshaie J; Cohen JE; Vranceanu AM
J Neurooncol; 2021 Nov; 155(2):125-132. PubMed ID: 34570301
[TBL] [Abstract][Full Text] [Related]
8. The impact of a mind-body program on multiple dimensions of resiliency among geographically diverse patients with neurofibromatosis.
Zale EL; Pierre-Louis C; Macklin EA; Riklin E; Vranceanu AM
J Neurooncol; 2018 Apr; 137(2):321-329. PubMed ID: 29275505
[TBL] [Abstract][Full Text] [Related]
9. The impact of a virtual mind-body program on resilience factors among international English-speaking adults with neurofibromatoses: secondary analysis of a randomized clinical trial.
Presciutti AM; Lester EG; Woodworth EC; Greenberg J; Bakhshaie J; Hooker JE; McDermott KA; Vranceanu AM
J Neurooncol; 2023 Jul; 163(3):707-716. PubMed ID: 37440099
[TBL] [Abstract][Full Text] [Related]
10. Baseline characteristics of adults with neurofibromatosis enrolled on a psychosocial randomized controlled trial.
Fishbein NS; Vranceanu AM; Mace RA
J Neurooncol; 2022 Sep; 159(3):637-646. PubMed ID: 35925531
[TBL] [Abstract][Full Text] [Related]
11. Virtual mind-body treatment for geographically diverse youth with neurofibromatosis: A pilot randomized controlled trial.
Lester E; DiStefano S; Mace R; Macklin E; Plotkin S; Vranceanu AM
Gen Hosp Psychiatry; 2020; 62():72-78. PubMed ID: 31841875
[TBL] [Abstract][Full Text] [Related]
12. Mind-Body Therapies for Opioid-Treated Pain: A Systematic Review and Meta-analysis.
Garland EL; Brintz CE; Hanley AW; Roseen EJ; Atchley RM; Gaylord SA; Faurot KR; Yaffe J; Fiander M; Keefe FJ
JAMA Intern Med; 2020 Jan; 180(1):91-105. PubMed ID: 31682676
[TBL] [Abstract][Full Text] [Related]
13. Mind-Body Treatment for International English-Speaking Adults With Neurofibromatosis via Live Videoconferencing: Protocol for a Single-Blind Randomized Controlled Trial.
Vranceanu AM; Zale EL; Funes CJ; Macklin EA; McCurley J; Park ER; Jordan JT; Lin A; Plotkin SR
JMIR Res Protoc; 2018 Oct; 7(10):e11008. PubMed ID: 30355560
[TBL] [Abstract][Full Text] [Related]
14. Diverse learners: learning disabilities and quality of life following mind-body and health education interventions for adults with neurofibromatosis.
Kanaya MR; Greenberg J; Bakhshaie J; Vranceanu AM
J Neurooncol; 2024 Apr; 167(2):315-322. PubMed ID: 38409461
[TBL] [Abstract][Full Text] [Related]
15. First report of quality of life in adults with neurofibromatosis 2 who are deafened or have significant hearing loss: results of a live-video randomized control trial.
Funes CJ; Mace RA; Macklin EA; Plotkin SR; Jordan JT; Vranceanu AM
J Neurooncol; 2019 Jul; 143(3):505-513. PubMed ID: 31049826
[TBL] [Abstract][Full Text] [Related]
16. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature.
Vranceanu AM; Merker VL; Park E; Plotkin SR
J Neurooncol; 2013 Sep; 114(3):257-62. PubMed ID: 23817811
[TBL] [Abstract][Full Text] [Related]
17. Minimal clinically important difference in the World Health Organization Quality of Life Brief (WHOQOL-BREF) for adults with neurofibromatosis.
Pietrzykowski MO; Vranceanu AM; Macklin EA; Mace RA
Qual Life Res; 2024 May; 33(5):1233-1240. PubMed ID: 38214851
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of QoL in neurofibromatosis patients: a systematic review and meta-analysis study.
Sanagoo A; Jouybari L; Koohi F; Sayehmiri F
BMC Neurol; 2019 Jun; 19(1):123. PubMed ID: 31189476
[TBL] [Abstract][Full Text] [Related]
19. Home practice and quality of life among patients with neurofibromatosis randomized to a mind-body intervention.
Funes CJ; Zale EL; Luberto CM; Vranceanu AM
Complement Ther Med; 2019 Feb; 42():114-118. PubMed ID: 30670227
[TBL] [Abstract][Full Text] [Related]
20. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis.
Merker VL; Bredella MA; Cai W; Kassarjian A; Harris GJ; Muzikansky A; Nguyen R; Mautner VF; Plotkin SR
Am J Med Genet A; 2014 Jun; 164A(6):1431-7. PubMed ID: 24664633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
